Share this article
Share this article
JERSEY CITY, N.J., Jan. 7, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people with amyotrophic lateral sclerosis (ALS) during the pandemic. The amendment gives patients the ability to consent to participate virtually, with the option to utilize telemedicine and home health agencies in lieu of hospital or in-office visits. In an effort to address the evolving concerns of the ALS community this year, we made it a priority to do what we can to support them during these unprecedented times, said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. With that in mind, we are thankful to be able to offer a potential alternative for patients to be able to participate in the REFINE-ALS study in a virtual setting when in-person assessments are not possible, enabling us to continue fostering scientific knowledge.
Search jobs Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS
JERSEY CITY, N.J., Dec. 22, 2020 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). The studies are sponsored by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA). As a company, we strive to always put patients first in our efforts to understand this debilitating disease, said Atsushi Fujimoto, President, MTPA. We hope this extension study will help provide important information to the ALS community.